Mycobacterium sherrisii visceral disseminated infection in an African HIV-infected adolescent  by Santoro, Francesco et al.
International Journal of Infectious Diseases 45 (2016) 43–45Case Report
Mycobacterium sherrisii visceral disseminated infection in an African
HIV-infected adolescent
Francesco Santoro a,*, Giulia Santoro b, Annalisa Del Giudice b, Rossella Perna b,
Francesco Iannelli a, Maria Immacolata Spagnuolo c, Eugenia Bruzzese c,
Andrea Lo Vecchio c,*
a Laboratory of Molecular Microbiology and Biotechnology (LAMMB), Department of Medical Biotechnologies, University of Siena, Siena, Italy
bUOC Microbiology and Virology, Ospedali dei Colli – AO V. Monaldi, Naples, Italy
c Section of Paediatrics, Department of Translational Medical Science, University of Naples Federico II, Naples, Italy
A R T I C L E I N F O
Article history:
Received 27 November 2015
Received in revised form 11 January 2016
Accepted 13 February 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
Mycobacterium sherrisii
Non-tuberculous mycobacteria
HIV
Abscess
Children
gyrB
S U M M A R Y
A case of visceral disseminated infection by Mycobacterium sherrisii in an African HIV-infected adolescent
with multiple abdominal abscesses is reported. Despite multiple drug resistance to ﬁrst-line antibiotics
in vitro, long-term treatment with clarithromycin, moxiﬂoxacin, and clindamycin, together with
appropriate antiretroviral treatment, resulted in clinical and radiological cure after 19 months of therapy
and follow-up.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Mycobacterium sherrisii is an opportunistic pathogen mainly
associated with HIV infection.1 It has recently been recognized as a
species phylogenetically related to Mycobacterium simiae.2 A few
cases of disseminated3 or localized4 infection have been reported
in the literature, some of them in non-HIV patients.5
2. Case report
A 17-year-old, HIV-infected, severely malnourished Eritrean
female was hospitalized in January 2014 for a clinical evaluation in
the Paediatrics Department of the University of Naples Federico II.
The girl had been diagnosed with HIV in Eritrea and had been
started on antiretroviral therapy (ART) in 2011. In 2013 she was
admitted to a local hospital in Eritrea with chronic diarrhoea,* Corresponding authors.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).abdominal discomfort, vomiting, haematemesis, and a low-grade
fever. She was diagnosed with pulmonary tuberculosis (TB) on the
basis of positive acid-fast smears and was started on a three-drug
anti-TB regimen lasting 3 months, followed by rifabutin for
another 4 months.
Upon arrival in Italy, the girl was severely malnourished with a
weight of 23.78 kg (Z-score 13.3), height of 132 cm (Z-score
4.78), body mass index (BMI) of 13.6 kg/m2 (BMI-for-age below
the ﬁrst percentile), and pubertal retardation (Tanner stage B1, G1,
PH1). Despite good compliance with ART and an HIV load of <40
HIV RNA copies/ml, her CD4+ cell count was 261/ml (12% of total
lymphocytes), deﬁning AIDS (stage C3 according to the US Centers
for Disease Control and Prevention paediatric classiﬁcation6).
A physical examination revealed reduced lung basal ventilation,
increased respiratory frequency (36 breaths/min), and decreased
thoracic excursion. The abdomen was tense and there was pain on
palpation of the left side. The presence of high C-reactive protein
(CRP; 88 mg/dl), hyperﬁbrinogenemia (644 mg/dl), normocytic
anaemia (haemoglobin 11.3 g/dl), and the persistent low-grade
evening fever (37.8 8C) suggested a chronic systemic inﬂammatory
process.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(4 mg/kg twice daily), abacavir (8 mg/kg twice daily), and
lopinavir/ritonavir (12 mg/kg twice daily of lopinavir), was
reviewed and adjusted according to weight variation and age.
High-resolution computed tomography (CT) of the thorax
revealed a parenchymal consolidation in the upper lobe of the left
lung. Because of the persistent haematemesis, an upper endoscopy
was performed to rule out gastrointestinal bleeding. Although the
girl had no cough (hence no haemoptysis), she reported frequent
swallowing of mucus, mainly at night, strengthening the suspicion of
a respiratory aetiology of the bleeding. In order to rule out TB, three
consecutive gastric aspirations and three sputum samples were sent
to the mycobacteriology laboratory. An interferon-gamma release
assay was ‘non-reactive’, presumably due to the low lymphocyte
count. As clinical and anamnestic data suggested a relapse of
the previous TB infection, treatment was started immediately with
isoniazid (10 mg/kg/day), ethambutol (20 mg/kg/day), pyrazina-
mide (35 mg/kg/day), and rifabutin (10 mg/kg/day) in accordance
with recent guidelines.7
Abdominal ultrasound and subsequent magnetic resonance
imaging of the abdomen revealed the presence of encapsulated
abscesses of about 20  30 mm located in the para-aortic and
mesenteric lymph nodes and a large abscess (82  30 mm) in the
left psoas muscle. The capsules of the abscesses showed signiﬁcant
contrast enhancement (Figure 1). Considering the previous
ineffective anti-TB treatment and the persistence of symptoms
and general inﬂammation after the onset of treatment, the psoas
abscess was drained percutaneously and the material was sent to
the microbiology laboratory for further analysis.
Acid-fast stains were performed on all specimens. Specimens
were inoculated onto both solid (Lowenstein–Jensen) and liquid
media (BACTEC MGIT 960). Smears made from gastric aspiration
were negative, while the smear from the abscess drainage material
was positive for acid-fast bacilli (>10 bacilli/ﬁeld). Two out of three
gastric aspiration specimens yielded growth in the liquid medium
after 6 and 7 days, while the abscess drainage material grew on
solid medium after 30 days of incubation. Both isolates were
identiﬁed as M. simiae by GenoType Mycobacterium AS (Hain
Lifescience, GmbH, Nehren, Germany). Therapy was thus modiﬁed
by the addition of oral clarithromycin and the discontinuation of
both isoniazid and pyrazinamide.Figure 1. Magnetic resonance imaging of the abdomen before (a) and after (b) intraveno
arrows.During the ﬁrst 7 days of this therapy, the patient experienced
an initial improvement (CRP 25 mg/dl, fever 37 8C); however, she
then began to have high fevers and an increase in inﬂammatory
markers. Ultrasound of the left psoas showed an increase in the
size of the abscesses and therefore a permanent drain was
positioned.
In order to conﬁrm the aetiological diagnosis, PCR ampliﬁca-
tion and sequencing of an internal fragment (964 bp) of the 16S
rDNA was performed on the two gastric aspirate isolates. BLAST
sequence analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi) with
the 16S ribosomal RNA sequence database showed 100% identity
with the sequence of M. sherrisii ATCC BAA-832 (GenBank
AY353699). Furthermore, a 1282-bp fragment of the gyrase
subunit B (gyrB) gene was ampliﬁed and sequenced with
primers IF882 (50-CAYGCSGGCGGCAAGTTCG-30) and IF883 (50-
GCCATCARSACGATCTTGTG-30). The sequence showed 92% iden-
tity with the gyrB gene from M. simiae strain KPM 1403
(GenBank AB014182) and was deposited at GenBank (accession
number KT182936). This conﬁrmed the 16S sequencing species
identiﬁcation.
Antibiotic therapy was again modiﬁed, switching from oral to
intravenous clarithromycin and adding amikacin (30 mg/kg/day),3
and successively moxiﬂoxacin (10 mg/kg/day) and co-trimoxazole
(15 mg/kg/day). During the ﬁrst 10 days of this multidrug therapy,
the patient experienced a general improvement, with resolution of
the fever and a reduction in the inﬂammatory markers. However,
the patient developed pancytopenia and severe hypoacusis (with
auditory brainstem response threshold shifts), thus both co-
trimoxazole and amikacin were discontinued.
In accordance with the recommendations for the treatment of
multidrug-resistant mycobacterial infections,7 empiric treatment
with linezolid (20 mg/kg/day) was added and there was an initial
clinical improvement in the fever and pain. However, due to the
limited response with regard to inﬂammation and to the relapse of
symptoms, linezolid was discontinued after 18 days of treatment.
Despite the relapsing–remitting pattern, the patient still
complained of abdominal pain, fever, and rare episodes of
haematemesis.
In April 2014, after 3 months of hospitalization and despite the
persistence of the low-grade fever, abdominal pain, and low grade
inﬂammation (CRP 10.7 mg/l), the patient returned to Eritrea onus gadolinium contrast injection. The larger abscess formations are indicated with
Table 1
In vitro antimicrobial susceptibility of the Mycobacterium sherrisii isolatea
Antibiotic MIC (mg/ml) Interpretative category
Isoniazid 4 -
Streptomycin 32 -
Ethambutol 16 R
Rifampicin 4 R
Amikacin 16 S
Clarithromycin 4 S
Ciproﬂoxacin 16 R
Linezolid 32 R
Moxiﬂoxacin 2 S
MIC, minimum inhibitory concentration; R, resistant; S, susceptible.
a MIC values were interpreted according to the Clinical and Laboratory Standards
Institute (CLSI) criteria. There are no CLSI interpretative criteria for isoniazid and
streptomycin.
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therapy was planned consisting of oral clindamycin, moxiﬂoxacin,
and clarithromycin (switched to oral after intravenous adminis-
tration), considering (1) the in vitro antimicrobial susceptibility
proﬁle (Table 1), (2) the side effects shown during hospitalization,
and (3) the availability of drugs in the country of origin. The
progression of the HIV infection was checked with viro-immuno-
logical markers, while the mycobacterial infection was monitored
by periodic blood sampling and CT of the abdomen.
A slow and progressive improvement was registered after the
patient’s return from Eritrea, with clinical amelioration, improve-
ments in the abdominal distension and pain, and resolution of the
vomiting, haematemesis, and fever within 2 months of discharge.
An abdominal CT scan performed after 1 year of treatment
demonstrated complete resolution of the psoas abscess and a
signiﬁcant reduction in the other abdominal lesions. As of
November 2015, the girl was in good overall clinical condition,
had gained 12 kg in weight (weight 36 kg, Z-score 4.3) and 13 cm
in height (height 145 cm, Z-score 2.7), and was having regular
menstrual cycles.3. Discussion
The diagnosis of non-tuberculous mycobacterial infections is
routinely performed with commercial kits, such as GenoType
Mycobacterium AS or INNO LiPA (Innogenetics, Ghent, Belgium);
however, in the case presented here, the diagnosis of M. sherrisii
infection required 16S rDNA sequencing. The antimicrobial suscep-
tibility pattern showed resistance to multiple ﬁrst-line antibiotics,
including most of those used for the empirical treatment of non-
tuberculous mycobacterial infections (i.e., isoniazid, ethambutol,
ciproﬂoxacin, and linezolid). After numerous antibiotic modiﬁca-
tions, a long-term antibiotic regimen including clindamycin,
clarithromycin, and moxiﬂoxacin was able to control, and appears
to have cured, the infection. This was evidenced by the signiﬁcant
weight gain and pubertal development. Effective control of the HIV
infection (HIV RNA copies <40/ml and CD4+ 18%, 435 cells/ml) was
also likely to have been an important factor in the favourable
outcome.
Ethical approval: Not required. Informed consent to report the
clinical data anonymously was provided by the caregivers.
Conﬂict of interest: The authors report no conﬂict of interest.
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